USA (+1 424) 258 5087

BG100. Red Abalone β-Glucuronidase

BG100
SKU – Pack Size Price ($USD)
BG100-10ML Get price
BG100-25ML Get price
Powder
SKU – Pack Size Price ($USD)
BG2.5-1MU Get price
BG2.5-2MU Get price


BG100™ is a highly efficient and partially purified molluscan beta-glucuronidase (bgluc) derived from ocean-fresh Red abalone Haliotis rufescens entrails. This hyperthermophilic bgluc catalyzes faster hydrolysis reactions. It demonstrates a wider substrate-adaptability and greater efficiency than Helix pomatia, Patella vulgata or even generic abalone-sourced bgluc. All clinical and forensic glucuronidated analytes are deconjugated in a one-run incubation. Complete recoveries are achieved in less than 90 minutes on both high and low concentrations of analytes.

– Deconjugate glucuronides (and sulfate esters in low proportions) by catalyzing hydrolysis.

– Screening and quantification of metabolized molecules in body fluids (urine, blood, plasma, meconium, bile)

BG100™ is superior to other molluscan beta-glucuronidase preparations by its ability to provide a comprehensive and complete hydrolysis in 18 to 90 minutes. It consistently hydrolyzes all opioids-opiates glucuronides including codeine-6-glucuronide (C6G) with over 87% recovery and has been validated in SAMHSA-certified drug-testing laboratories (Technical Note available on request). Herbal cannabinoids (THCCOOH, THC, CBD,…) and benzodiazepines are recovered in the same incubation. BG100™ has also been validated with a series of emerging designer drugs such as synthetic cannabinoids (spice, K2,…) and synthetic cathinones (MDPV etc). In 2013 the US-National Institute on Drug-Abuse (NIDA) observed that metabolites of synthetic cannabinoids can be hydrolyzed with 10-fold less bgluc than with generic abalone preparations. As a result a high-throughput screening method was made possible.

BG100™ is LC-column compatible and enables high-throughput methods. Matrix effect or even column-clogging are common issues particularly with LC-MS/MS or HPLC users. BG100™ goes through an advanced purification process relying on ocean-fresh (never freeze-dried) Red abalone entrails. The resultant enzyme preparation BG100™ is optimized to minimize matrix effects, improve data quality, and achieve short injection-to-injection cycles. In high-throughput drug-testing BG100™ contributes to no or reduced sample preparation such as dilute-and-shoot or protein precipitation. In any case, quality of readings is increased through less background-noise interferences. Improved LOQ and LOD bring further accuracy in TDM (e.g. low-benzodiazepines), workplace drug-testing and forensic (e.g. designer drugs) as well as anti-doping and clinical steroid-profiling.

In particular BG100™ replaces Helix pomatia (G7017 type HP-2) beta-glucuronidase, is autosampler-friendly, provides a two to ten-fold higher hydrolysis velocity and increases reading quality. Former overnight hydrolysis incubations are performed in less than 90 minutes, eliminating the risk of conversions and analyte instability.

– Reduce incubation time down to 3-90 minutes with recovery rates >90%.

– Simplify laboratory workflow with one sample preparation: one hydrolysis – one analysis .

– Guarantee highest recovery rates at both high and low substrate concentrations.

– Enable high-throughput liquid chromatography method.

– Decrease matrix effect.

– Increase quality of readings.

– Extend column lifetime and chromatography instruments up-time.

– Optimized hydrolysis protocols (Technical Notes) and technical support available.

BG100
β-Glucuronidase activity > 100,000 U/ml (Phenolphthalein-β-D-glucuronide as substrate)
Sulfatase activity < 8,000 U/ml
Form Liquid amber solution, autosampler friendly
Storage temperature +2 – +8 °C
Powder
β-Glucuronidase activity 1,000,000 – 3,200,000 U/g (Phenolphthalein-β-D-glucuronide as substrate)
Sulfatase activity < 150,000 U/g
Form light brown lyophilized powder
Storage temperature -20 °C
  1. Romberg, R.W. and Lee, L., J. Anal. Toxicol., 19, 157-162 (1995).
  2. Marin, S.J. and McMillin, G.A. Methods Mol Biol., 603, 89-105 (2010).
  3. Dahn, T., et al., Methods Mol Biol., 603, 411-422 (2010).
  4. Ferchaud, V., et al., Analyst., 125, 2255-2259 (2000).
  5. Impens, S., et. al., Anal Chim Acta, 586, 43-48 (2007).
  6. Bergamaschi, M.M., et al., Anal Bioanal Chem., [Epub ahead of print] (2013).
  7. Jagerdeo, E. and Schaff, J.E. J. Chromatogr. B., 1027, 11-18 (2016).
  8. Cliburn, K.D. and Kemp, P.M. FAA Report, DOT/FAA/AM-15/6 (2015).
  9. Scheidweiler, K.B. et. al., Anal Bioanal Chem, 407(3), 883-897 (2015).
  10. Desrosiers, N.A. et. al., Drug Test. Anal., 7(8), 684-694 (2015).
  11. Anizan, S., et. al., Anal Chim Acta, 827, 54-63 (2014).